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Abstract
Background: To assess the role of Thymidine Phosphorylase and b-tubulin III in clinical outcome of Chinese
advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Methods: The clinical data and tumor biopsies prior treatment from 33 advanced gastric cancer patients receiving
capecitabine plus paclitaxel (cohort 1, experimental group) and 18 patients receiving capecitabine plus cisplatin
(cohort 2, control group) in Beijing Cancer Hospital from July 2003 to December 2008 were retrospectively
collected and analyzed for Thymidine Phosphorylase and b-tubulin III expressions by immunohistochemistry. The
relationships between expressions of biomarkers and response or survival were determined by statistical analysis.
Results: The median age of 51 patients was 57 years (range, 27-75) with male 34 and female 17, and the response
rate, median progression-free survival and overall survival were 43.1%, 120d and 265d. Among cohort 1, the
response rate, median progression-free survival and overall survival in b-tubulin III positive (n = 22) and negative
patients (n = 11) were 36.4%/72.7% (positive vs negative, P = 0.049), 86d/237d (P = 0.046) and 201d/388d (P =
0.029), respectively; the response rate (87.5% vs 14.3%, P = 0.01) and median progression-free survival (251d vs 84d,
P = 0.003) in Thymidine Phosphorylase positive & b-tubulin III negative patients (n = 8) were also significantly
higher than those in Thymidine Phosphorylase negative & b-tubulin III positive patients (n = 7). There was no
correlation between b-tubulin III expression and response or survival among cohort 2 (n = 18).
Conclusions: In Chinese advanced gastric cancer, Thymidine Phosphorylase positive & b-tubulin III negative might
predict response and prognosis to capecitabine plus paclitaxel chemotherapy. Further prospective evaluation in
large samples should be performed to confirm these preliminary findings.
Background
Gastric cancer remains one of the most common causes
of cancer death worldwide [1], especially in China [2].
Although the improvement of diagnostic methods
enables some patients to receive radical cure at early
disease, about 40% patients still miss the opportunity of
radical cure at the time of diagnosis, furthermore, about
50% patients occur relapse and metastasis after opera-
tion. For these patients, chemotherapy is still the main
method general accepted in the world. Several agents
are now available for the systemic chemotherapy of
patients with gastric cancer, including fluoropyrimidines,
platinum, taxanes and so on. But fluoropyrimidines are
fundamental in gastric cancer. For advanced gastric can-
cer patients (AGC), combination chemotherapy with
two or three drugs is most common with superiority
compared to best supportive care in first-line or second-
line therapy [3-6].
Capecitabine is an orally-administered chemothera-
peutic agent which was designed to generate 5-Fluor-
ouracil (5-FU) preferentially in tumors. It is a prodrug
which is converted to 5-FU in the tumors through a
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ary metabolites involved in. At the last enzymatic step,
the metabolite 5’-deoxy-5-fluorouridine (5’-DFUR) is
converted to 5-FU by Thymidine Phosphorylase (TP)
which is more active in tumor tissues than in normal
tissues [7]. So, the overexpression of TP in tumor tissues
can increase the concentration of 5-FU and thus
enhance the anticancer effect. Current evidences indi-
cate that the expression level of TP may influence the
clinical outcome of capecitabine in non-small cell lung
cancer, gastrointestinal adenocarcinoma, breast cancer,
head and neck cancer, and so on [8-11]. Two large
phase III clinical trials showed that capecitabine could
substitute 5-FU in clinical administration [12,13]. Also
capecitabine combined with cisplatin or paclitaxel has
been proved to be an effective combination regimen
used in patients with advanced gastric cancer as first-
line or second-line treatment [13-15].
Taxane including paclitaxel (PTX) and docetaxel, is
another active antitumor agent for gastric cancer. Tax-
ane binds to b-tubulin, which is one of the major com-
ponents of microtubule, and exerts its growth-inhibitory
effects through the stabilization of microtubule, resulting
in the growth arrest of tumor cells at the G2/M phase
[16]. Several mechanisms have been suggested as
responsible for taxane resistance: ① The overexpression
of MDR1 gene which encodes P-glycoprotein able to
efflux taxanes and other cationic drugs, thereby hamper-
i n gd r u gr e t e n t i o n[ 1 7 ] ;② Point mutation in tubulin
has been identified to be responsible for taxane resis-
tance [18,19]. ③ The selective overexpression of b-tubu-
lin isotypes is another mechanism of resistance [20]. Up
to now, at least seven distinct b-tubulin isotypes (classes
I, II, III, IVa, IVb, V and VI) have been reported in
human, with a complex distribution pattern in various
tissues [20]. Some researches found the presence of
class III b-tubulin (b-tubulin III, TUBB3) inhibited the
assembly of b-tubulin subunits promoted by paclitaxel
[21] and TUBB3 expressed in some paclitaxel-resistant
cells [22]. Many preclinical studies have shown high
expression levels of TUBB3 are associated with pacli-
taxel resistance in human lung cancer [23], ovarian can-
cer [22], prostate cancer [24] and breast cancer [25] cell
lines. In studies of lung cancer, breast cancer and ovar-
ian cancer, there are reverse relations between TUBB3
expression and paclitaxel efficacy or prognosis of
patients [26-28].
Now that the target of paclitaxel is b-tubulin, and
study had reported that there were rare mutations in b-
tubulin for gastric cancer (no mutations were found in
50 tumor samples) [29], we considered that the overex-
pression of TUBB3 was the most probable mechanism
of paclitaxel resistance in gastric cancer. This study was
designed to demonstrate the clinical implications of TP
and TUBB3 expressions in capecitabine plus paclitaxel
chemotherapy for advanced gastric cancer patients, and
to identify potential predictors for patients with gastric
cancer treated with capecitabine plus paclitaxel.
Methods
Patients Eligibility
All patients in this study were retrospectively collected
as following criteria: patients had histologically con-
firmed metastatic gastric adenocarcinoma and at least
one measurable lesion according to the response evalua-
tion criteria in solid tumors guidelines [30]; patients
were treated by capecitabine plus paclitaxel or cisplatin
in gastrointestinal department of Beijing Cancer Hospi-
tal from July 2003 to December 2008, and had com-
pleted at least two cycles of chemotherapy; no any
chemotherapy except for neoadjuvant or adjuvant che-
motherapy (adjuvant chemotherapy completed over 12
months) was done; all patients underwent endoscopic
biopsy from primary stomach before chemotherapy.
Treatment Regimens
The first-line chemotherapy regimens with capecitabine
plus paclitaxel or cisplatin were administered to patients
as following: capecitabine (Roche Laboratories Inc., Nut-
ley, NJ) was given orally at a dose of 1,250 mg/m
2 twice
daily from day1 (d1) to day14 (d14) of 3-weeks cycle;
paclitaxel (Hainanhaiyao Co., Ltd., China) was given at a
dose of 80 mg/m
2 by a 180-min i.v. infusion on d1 and
d8 of each cycle; cisplatin (Qilu Pharmaceutical CO.,
LTD., China) was given at a dose of 80 mg/m
2 by a
240-min i.v. infusion on d1 of each cycle. Treatment
was continued until disease progression or unacceptable
toxicity, or patients/physicians’ decision.
Response Evaluation
Chemotherapeutic response was evaluated every two
months by computed tomography (CT) according to
the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria. Patients were categorized by com-
plete response (CR), partial response (PR), stable disease
(SD), and progressive disease (PD). CR and PR patients
were defined as responders, SD and PD patients as non-
responders. The progression-free survival (PFS) and
o v e r a l ls u r v i v a l( O S )w e r ec a l c u l a t e df r o mt h ef i r s td a y
of therapy to disease progression and death from any
cause, respectively.
Immunohistochemistry analysis for TP and TUBB3
All tumor samples were retrospectively collected from
patients, and two step method of immunohistochemis-
try (IHC) was used to detect TP and TUBB3 in tumor
sections. Formalin-Fixed Paraffin-Embedded tissue sec-
tions with 4 μm thick were deparaffinized in xylene
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in 0.01M citrate buffer (pH 6.0), sections were treated
with endogenous peroxidase confining liquid (Beijing
CoWin Biotech Co., Ltd., Lot. CW0117) for 10 min.
Sections were rinsed and incubated with TUBB3 and
TP (Beijing CoWin Biotech Co., Ltd.) monoclonal anti-
bodies for 60 min, respectively. After rinsing in phos-
phate buffered saline (PBS), the sections were
incubated with general type IgG-HRP Polymer (Beijing
CoWin Biotech Co., Ltd., Lot. CW0117) for 10 min,
followed by chromogenic 3,3’-Diaminobenzidine tetra-
hydrochloride dihydrate (DAB) for about 2-7min.
Finally, sections were conterstained with hematoxylin
for 1 min followed by dehydrated in graded alcohols,
cleared in xylene, and covered with coverslips. Each
experiment included negative control. Sections were
examined and scored by two independent professional
pathologists of pathology department without any
knowledge of this study. TP protein was distributed in
cytoplasm and nuclear, TUBB3 in cytoplasm. Staining
was graded for intensity of staining according to pre-
vious description [31]. Briefly, intensity of staining
(1, weak; 2, moderate; 3, strong) and percentage of
cells stained (1, 0%~10%; 2, 11%~50%; 3, 51%~100%)
were calculated. At last, the expression levels were
considered to be positive or negative based on the
median staining score (intensity score plus percentage
score) as following: negative for score ≤ 3, positive for
score > 3.
Statistical Analysis
According to TP and TUBB3 protein expression levels,
patients were divided into two groups (positive and
negative). The relationships between TP, TUBB3 expres-
sions and response to capecitabine plus paclitaxel or cis-
platin were analyzed using Fisher’s exact test. Kaplan-
Meier curves and log-rank test were used to analyze the
association between expression levels of biomarkers and
survival. Statistical analysis was done using SPSS 13.0
(SPSS Inc, Chicago, Illinois, USA).
Results
Patient Demographics
Fifty-one patients were included in this study between
July 2003 to December 2008 in our hospital with male
34, female 17, median age 57 years (range 27-75 years).
Thirty-three patients (male 20, female 13, median age
57 years [range 27-74 years]) received capecitabine plus
paclitaxel with a median 6 cycles of chemotherapy
(cohort 1) and eighteen patients (male 14, female 4,
median age 57 years [range 42-75 years]) received cape-
citabine plus cisplatin with a median 6 cycles of che-
motherapy (cohort 2). The characteristics of 51 patients
are presented in Table 1.
Response Evaluation and Survival
Up to February 2010, all patients had been evaluable for
response and 43 patients died. The overall response rate
(CR+PR) in 51 patients was 43.1%, with 22 partial
Table 1 Patient Demographics and Clinical Characteristics
Characteristic Cohort 1 (n = 33) Cohort 2 (n = 18) Total (n = 51)
No. of Patients % No. of Patients % No. of Patients %
Sex
Male 20 60.6 14 77.8 34 66.7
female 13 39.4 4 22.2 17 33.3
Age, years
Median 57 57 57
Range 27-74 42-75 27-75
KPS
90-100 23 69.7 14 77.8 37 72.5
70-80 10 30.3 4 22.2 14 27.5
Sites of metastatic disease
Liver 12 36.4 6 33.3 18 35.3
Lung 1 3.0 4 22.2 5 9.8
Lymph nodes 33 100 17 94.4 50 98.0
Peritoneum 6 18.2 3 16.7 9 17.6
Others* 8 24.2 4 22.2 12 23.5
Histological differentiation
#
Poor 25 75.8 11 61.1 36 70.6
Good 8 24.2 7 38.9 15 29.4
NOTE: *Including ovary, adrenal glands, subcutaneous of abdominal wall, pelvic cavity, bone and thoracic cavity.
#Poor, including poorly differentiated
adenocarcinoma, signet ring cell carcinoma and mucinous adenocarcinoma; Good, including moderate-well differentiated adenocarcinoma. KPS, Kamofsky
performance status.
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(35.3%), and 11 patients with progressive disease
(21.6%). The median PFS and OS of 51 patients were
120 days and 265 days, respectively. There were no sig-
nificant differences of response and survival between
cohort 1 and cohort 2 (Table 2). The response rate,
median PFS and OS in cohort 1 and cohort 2 were
48.5%, 120 days, 252 days and 33.3%, 116 days, 265
days, respectively.
TP IHC and Response, Survival
Negative and positive staining for TP protein in 51
tumor samples were 26 and 25 samples (Figure 1, left
lane). Of the 25 patients with positive TP, there were 14
responses (56%), compared with 8 of 26 responses
(30.8%) seen in negative TP tumors (P = 0.069, Table
3). Also, the median PFS and OS in TP positive samples
were longer than that in TP negative samples, but sig-
nificant difference only existed in OS (P = 0.017) not in
PFS (P = 0.613) between two groups (Table 3).
TUBB3 IHC and Response, survival
IHC of TUBB3 was done in cohort 1 and cohort 2,
negative and positive staining for TUBB3 in cohort 1
(33 samples) were 11 and 22 samples (Figure 1, right
lane). Among cohort 1, of the 22 patients with positive
TUBB3, there were 8 responses (36.4%), compared with
8 of 11 responses (72.7%) seen in negative TUBB3
tumors (P = 0.049); also, the median PFS (P = 0.046)
and OS (P = 0.029) in TUBB3 positive samples were
much shorter than those in TUBB3 negative samples
(Table 4 and Figure 2). Among cohort 2, the response
rates in TUBB3 negative patients (n = 7) and positive
patients (n = 11) were 28.6% and 36.4%, respectively (P
= 0.73). Also, there weren’t correlations between TUBB3
expressions and median PFS (P = 0.562) or OS (P =
0.633) in cohort 2 (Figure 3).
TP, TUBB3 IHC and Response, survival
Among cohort 1, TP positive & TUBB3 negative stain-
ing was 8 samples, with 7 responses (87.5%), but for TP
negative & TUBB3 positive staining samples, only 1 of 7
responses (14.3%) (P = 0.01, Table 5). The median PFS
(251d) and OS (393d) in TP positive & TUBB3 negative
staining samples were longer than those (PFS: 84d, OS:
196d) in TP negative & TUBB3 positive staining sam-
ples, although there was no statistical difference of OS
between two groups (P = 0.003 for PFS, P = 0.439 for
OS, Table 5 and Figure 4). There were 15 samples (8
responses, 53.3%) displaying TP positive & TUBB3 posi-
tive staining with median PFS 122d and median OS
207d, and 3 samples (all with SD) displaying TP nega-
tive & TUBB3 negative staining.
Table 2 Response and Survival for all patients
Cohort 1 (n =
33)
Cohort 2 (n =
18)
P Total (n =
51)
Outcome No. % No. % No. %
CR+PR No. 16 48.5 6 33.3 22 43.1
SD No. 11 33.3 7 38.9 18 35.3
PD No. 6 18.2 5 27.8 11 21.6
Response rate 16 48.5 6 33.3 0.668 22 43.1
Median PFS (days) 120 116 120
95% CI 77.2-162. 8 0-267.1 0.377 79.7-160.3
Median OS (days) 252 265 265
95% CI 157. 5-346.5 107.0-423.0 0.354 181.0-349.0
NOTE: PFS, progression-free survival; OS, overall survival; 95% CI: 95%
confidence interval
Figure 1 IHC presenting TP and TUBB3 expressions
(magnification, ×400). A, TP negative; B, TP positive; C, TUBB3
negative; D, TUBB3 positive.
Table 3 Association Between TP Expression and Response
or Survival
TP Staining (n = 51)
Positive Negative
CR+PR No.1 4 8
SD No.5 1 3
PD No.6 5
Response rate (%) 56 30.8
P 0.069
Median PFS (days)
(95% CI)
156
(71.5-240.5)
107
(66.7-147.3)
P 0.613
Median OS (days)
(95% CI)
365
(123.0-567.0)
214
(74.8-317.2)
P 0.017
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The treatment of gastric cancer is still a troublesome
problem worldwide, and up to now there is not sys-
tematic standard regimen for gastric cancer. Over 50%
patients couldn’t respond to chemotherapy with the
major obstacle is drug resistance. So how to improve
t h er e s p o n s ea n de x t e n dt h el i f eo fp a t i e n t si s
requested urgently. At present, the regimen of plati-
num (cisplatin, oxaliplatin, etc.) combined with fluor-
ouracil (5-FU, capecitabine, etc.) is most used for
gastric cancer in China. Capecitabine is a new type
flurouracil carbamates antitumor agent and widespread
used by tumor patients due to its convenient adminis-
tration, well tolerance, definite effect and low side
effect. Animal experiments have shown that many
drugs, such as irinotecan, oxaliplatin, cisplatin and
paclitaxel, had synergistic effect with capecitabine
[32-34], and capecitabine plus paclitaxel or cisplatin
regimens have been considered as desirable che-
motherapy in clinical studies [13-15].
Based on our results, the response rate of capecitabine
plus paclitaxel or cisplatin was 48.5% and 33.3%, respec-
tively. However, although these regimens were effective
in gastric cancer, over an half patients failed to respond
due to drug resistance. So if we can find some predictive
biomarkers for capecitabine plus paclitaxel to guide
treatment of patients, there must be a very great
improvement for response and survival. TP is a key
enzyme in the metabolic pathway of capecitabine. TP
enzyme, also called tumor related angiogenesis factor, is
higher expressed in tumor tissues than in normal tis-
sues, then the concentration of 5-FU in tumor tissues is
raised followed by enhanced antitumor activity. In our
results, the response rate, PFS and OS for TP positive
patients are all higher than that in TP negative patients,
which is similar with the results by other researchers
[8-11]. According to abover e s u l t s ,w ea n a l y z e dT P
expression in advanced gastric cancer and found the
overall survival of TP positive patients was much better
than that in TP negative patients. However, in different
studies of colorectal cancer, data about the prognostic
or predictive value of TP were conflicting: Meropol NJ
et al [35] reported TP expression might be a predictive
marker for capecitabine response, but Koopman et al
[36] found TP expression didn’t show a predictive or
prognostic value for capecitabine combination
chemotherapy.
Table 4 Association Between TUBB3 Expression and
Response or Survival
TUBB3 Staining
Positive Negative
CR+PR No.8 8
SD No.9 2
PD No.5 1
Response rate (%) 36.4 72.7
P 0.049
Median PFS (days)
(95% CI)
86
(40.9-131.1)
237
(19.4-454.6)
P 0.046
Median OS (days)
(95% CI)
201
(182.5-253.5)
388
(67.6-708.4)
P 0.029
Figure 2 PFS and OS curves for TUBB3 negative and positive patients receiving capecitabine plus paclitaxel.
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isms about its resistance have been studied for a long
time. Microtubule is the target of paclitaxel which
induces microtubule stabilization, inhibits microtubule
dynamics and interrupts cell divisions. Studies showed
that TUBB3 high expressed in paclitaxel-resistant cells
[37] and after transfecting TUBB3 cDNA into mamma-
lian cells, cells with TUBB3 expression displayed resis-
tant to paclitaxel [38]. Also in other studies about breast
cancer, ovary cancer, head and neck neoplasms, there
were relationship between TUBB3 expression and
response or survival of paclitaxel. We studied the corre-
lation in 33 samples treated with capecitabine plus pacli-
taxel, and found that the response rate for TUBB3
negative patients was 72.7%, but only 36.4% in TUBB3
positive patients. Moreover, in cohort 1, the prognosis
of TUBB3 negative patients was much better than that
of TUBB3 positive patients. Our results indicated there
was not relationship between TUBB3 expression and
response or survival in patients receiving capecitabine
plus cisplatin, so TUBB3 expression could act as a pre-
dictor of paclitaxel efficacy.
TP could be upregulated after the treatment of taxane
in preclinical trial [39], we analyzed the relationship
between TP, TUBB3 expressions and the response or
survival of patients. Interestingly, the response rate in TP
positive & TUBB3 negative patients was 87.5%, but only
14.3% in TP negative & TUBB3 positive patients. This
result will need to be further confirmed in future studies.
Recently, many studies put the sights into genomic
polymorphisms in genes involved in drug metabolic
pathway and correlated with the target of agents. Few
genes have been used to guide clinical medication, such
as K-RAS [40], C-KIT [41], EGFR [42], Her-2 [43], and
so on, but for most drugs there were no predictive mar-
kers. According to our results, TP and TUBB3 may be
Figure 3 PFS and OS curves for TUBB3 negative and positive patients receiving capecitabine plus cisplatin.
Table 5 Association Between TP, TUBB3 Expressions and Response or Survival
TP, TUBB3 Staining
TP positive & TUBB3 negative TP negative & TUBB3 positive
CR+PR No.7 1
SD No.1 3
PD No.0 3
Response rate (%) 87.5 14.3
P 0.01
Median PFS (days)
(95% CI)
251
(146.4-354.6)
84
(52.5-110.7)
P 0.003
Median OS (days)
(95% CI)
393
(340.9-530.8)
196
(70.3-461.7)
P 0.439
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vival of capecitabine and paclitaxel.
To summarize our results, our findings demonstrate
it’s possible that overexpression of TUBB3 is the major
reason of paclitaxel resistance in gastric cancer, and
positive TP & negative TUBB3 expressions might pre-
dict response and prognosis to capecitabine plus pacli-
taxel chemotherapy in AGC.
Conclusions
Our findings suggested that, in Chinese advanced gastric
cancer, TP positive & TUBB3 negative expressions
might predict response and prognosis to capecitabine
plus paclitaxel chemotherapy. Further prospective eva-
luation in large samples should be performed to confirm
these preliminary results.
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